Learn more

ANGIOLAB INC

Overview
  • Total Patents
    58
  • GoodIP Patent Rank
    185,389
About

ANGIOLAB INC has a total of 58 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, foods and drinks and organic fine chemistry are MD BIOALPHA CO LTD, PROYECTO EMPRESARIAL BRUDY SL and MSI METHYLATION SCIENCES INC.

Patent filings per year

Chart showing ANGIOLAB INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Kim Min Young 27
#2 Kim Min-Young 22
#3 Park Byung Young 18
#4 Lee Hee Suk 14
#5 Park Byung-Young 12
#6 Park Byeong Yeong 12
#7 Park Eun Kyu 10
#8 Hahm Jong Cheon 10
#9 Mun Chang Hui 9
#10 Park Eun-Kyu 9

Latest patents

Publication Filing date Title
KR102229760B1 Fraction of Melissa Leaf Extract and Novel Pharmaceutical Composition Comprising the Same
KR102121969B1 Pharmaceutical Composition Comprising Fraction of Melissa Leaf Extract
KR20200091925A Composition comprising a horse chestnut extract
KR20180001047A Composition of an extract of horse chestnut
KR20090020285A A fraction of melissa leaf extract and a composition comprising the same
KR20080071017A Method for producing extract of horse chestnut leaf
KR100645385B1 Composition for anti-obesity
KR20060115526A Composition for angiogenesis inhibitor
KR100620751B1 Composition for radiosensitization
US2006246157A1 Composition for the prevention or treatment of diseases associated with angiogenesis
KR20040062018A Pharmaceutical compositions for angiogenesis inhibition containing phenylthionocarbamate derivatives or its pharmaceutically acceptable salts
EP1438059A1 Composition containing horse chestnut extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
KR20030035912A Composition for inhibiting angiogenesis containing an extract of horse chestnut
KR20030071993A Compositions comprising Nm23 protein for the use of matrix metalloproteinase inhibitor and angiogenesis inhibitor
KR20030060384A Expression system of human serum albumin-timp-2 fusion protein and recombinant human serum albumin- timp-2 protein
EP1349558A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
KR20020046193A Composition containing melissa extract for the use of angiogenesis inhibitor
KR20030036993A Pharmaceutical composition for inhibiting matrix metalloproteinase activity comprising chalcone or its derivatives
WO0211745A1 Composition containing ginkgo biloba that inhibit angiogenesis and matrix metalloproteinase
WO0209741A1 The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis